Chiara Mercinelli

Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy - a combined analysis of #PURE01 #SURE02 #NureCombo @CMercinelli @Anto_cigliola @BrigidaMaiorano et al. @SanRaffaeleMI @MyUniSR #TMB @FoundationATCG clinical-genitourinary-cancer.com/article/S1558-…

🚨 🚨🚨New Editorial in @EurUrolOncol ! #PROTEUS trial: a landmark study, but are we ready for treatment intensification in high-risk PCa? We discuss the evidence, unanswered questions, biomarkers, and the evolving role of multimodal care. sciencedirect.com/science/articl…

Is the PROTEUS trial practice-changing? Or should we be more cautious? For the first time, a phase III trial demonstrated that perioperative treatment with apalutamide plus androgen deprivation therapy improves pathological response and metastasis-free survival in men with high-risk localized prostate cancer undergoing radical prostatectomy. Some key reflections: 🔹 A landmark study. PROTEUS provides proof of concept that intensified perioperative systemic therapy can modify the biology of localized prostate cancer and potentially reshape future treatment paradigms. 🔹 A modest absolute benefit. While statistically significant, the absolute improvement in 5-year metastasis-free survival was relatively small. This highlights the need to carefully balance efficacy against toxicity, cost, and the risk of overtreatment. 🔹 An innovative but challenging endpoint. PROTEUS is the first randomized phase III trial to include PSMA-PET-detected metastases within its primary metastasis-free survival endpoint. This reflects modern imaging practice, but PSMA-PET-based MFS has not yet been validated as a surrogate for overall survival. As our imaging becomes more sensitive, we must ensure that our clinical endpoints remain meaningful for patients. 🔹 Patient selection remains the key question. High-risk prostate cancer is not a single disease. The future lies in identifying the patients who truly benefit from treatment intensification through better biological and molecular stratification, rather than applying a “one-size-fits-all” approach. PROTEUS is undoubtedly a landmark trial. However, its greatest contribution may not simply be demonstrating that “more treatment is better,” but rather opening the door to a more nuanced discussion about who should receive intensified therapy, how we should measure success, and how we can personalize treatment for patients with high-risk localized prostate cancer. euoncology.europeanurology.com/article/S2588-… #ProstateCancer #Urology @GiuliaMarvaso84 @CMercinelli @GGandaglia @PBlanchardMD @roodvdb @GGiannarini @MRoupret @EurUrolOncol @Lara__Rodriguez @foxal72

How well are we really #protecting #bones of #prostatecancer patients on ADT?💉ADT #impact on bone mineral density, fracture risk, and long-term skeletal health is often underaddressed 📢We need the voice of #radiationoncologists, #medicaloncologists, and #urologists worldwide

🌍 Penile cancer care varies dramatically across the world. From HPV integration and organ preservation to nodal staging and survivorship, major knowledge gaps remain in this rare disease. This review identifies the key research priorities in penile cancer care. 📖 Read here: bmjoncology.bmj.com/content/5/1/e0… @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @TataMemorial @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud @VedangMurthy

A productive weekend working on PIONEER and real-world data in localized prostate cancer. We used the study-a-thon to define a focused research portfolio using broad real-world datasets: baseline characteristics, first-line treatment, subsequent treatment, metastasis after primary therapy, adverse events, and overall survival. The potential research lines include treatment patterns, disease trajectory, outcomes in elderly and frail patients, post-primary treatment sequencing, adverse-event burden, and long-term survivorship. We also aligned on key endpoints: metastasis-free survival, ADT-free survival, local-treatment-free survival, time to first subsequent local or systemic treatment, and overall survival. Most excitingly, we have identified more than 500,000 patients with localized prostate cancer across our datasets. But beyond the numbers, this weekend was also a reminder that bringing the right people together, clinicians, researchers, data scientists, and collaborators, is what turns ideas into projects and projects into impact. This is a huge opportunity to generate meaningful real-world evidence in prostate cancer. Big data is coming, stay tuned 🤞 @NICOLETTIRosse1 @Sevans_axelsson @dr_rajwa @Uroweb @CMercinelli #PIONEER #ProstateCancer #RealWorldData

MTAP loss and key alteration detection via liquid biopsy explored in #BladderCancer. @CMercinelli @MyUniSR joins @UroDocAsh @UTMDAnderson to discuss liquid biopsy detection of MTAP loss in bladder cancer. Liquid biopsies provide non-invasive serial monitoring throughout treatment lines, enabling treatment decision guidance for metastatic disease without requiring archived tissue specimens. #WatchNow on UroToday > bit.ly/4cLY8Xv

The unmissable moment of our annual #GUoncology .#cocktailparty has come! Thanks to the entire group for growing so well @SanRaffaeleMI @MyUniSR @AssPalinuro #TerrazzaDuomo21 #Milan @CMercinelli @vale_tateo @Anto_cigliola @BrigidaMaiorano

More data on advanced automated use of MRI in #bladdercancer A two-stage foundation model for bladder tumor segmentation: An international multi-site study - European Journal of Radiology Artificial Intelligence ejrai.com/article/S3050-… @SanRaffaeleMI @MyUniSR @MSKCancerCenter @OncoAlert @urotoday

Pleased to share our next #ASCO26 @JCO_ASCO Simultaneous Publication Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer #SURE-01 Trial following our previous #SURE02 29% pCR rate with monotherapy supports TROP2 as a reliable target in MIBC Biomarkers point to the Payload TOP1 effect rather than the Ab target @SanRaffaeleMI @MyUniSR @BrigidaMaiorano @vale_tateo @Anto_cigliola @CMercinelli @GiorgioBre et al. ascopubs.org/doi/pdf/10.120…

@MyUniSR @SanRaffaeleMI

Grateful to @UroToday and @UroDocAsh for this conversation on #MTAPloss detection via #liquidbiopsy in #BladderCancer Serial, non-invasive monitoring across treatment lines➡️ a key step toward biomarker-driven decision making. Another great collaboration with @FoundationATCG

🚨 Patient-led insights in #PenileCancer Key takeaways: 🔹 Delays in diagnosis remain common 🔹 Psychological and psychosexual support is underprovided 🔹 Peer support is highly valued but inconsistently accessible A powerful reminder that improving outcomes in rare cancers requires listening to patient voices. 🔗 doi.org/10.1016/j.sonc… @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @MDAndersonNews @MoffittNews @TataMemorial @MUSC_UroOnc @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud

Always a pleasure to meet you @shilpaonc ✨

#ASCOGU2026 Rapid orals The amazing @AndreaNecchi rocks the stage with SunRise 2 trial in MIBC. Pragmatic trial of Gem-iDRS + cetrelimab vs concurrent CRT, no improvement in BI-EFS vs CRT. Trial stopped early. 1st trial with CRT in experimental arm. CRT continues as standard for now. @OncoAlert @Uromigos

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

@ChiaraRe @EAUYAU_RenalCa @EAUYAUrology Congrats!!

I’m proud and honored to share that I will be joining the @EAUYAU_RenalCa Working Group as an Associate Member. Truly looking forward to starting this new chapter and working alongside inspiring international colleagues!

@NICOLETTIRosse1 @unipa_it @alchiede @Nicp85Pavan Always the number 1! Congrats

Proud to share that I’ve been appointed Assistant Professor of Urology / Tenure Track Researcher at @unipa_it, under the mentorship of Prof. @alchiede and Prof. @Nicp85Pavan I’m more than honored to represent Sicily and woman in Uro-oncology Research

@LuisMedinaMD @IBCG_BladderCA @UroDocAsh @UrogerliMD @shilpaonc @AndreaNecchi @MyUniSR @SanRaffaeleMI Thanks Luis!!

@CMercinelli @IBCG_BladderCA @UroDocAsh @UrogerliMD @shilpaonc @AndreaNecchi @MyUniSR @SanRaffaeleMI Congrats Chiara!

Grateful and honored to be welcomed as a member of the @IBCG_BladderCA Thank you for this recognition and for the inspiring work you do every day. Excited to be part of this journey! @UroDocAsh @UrogerliMD @shilpaonc @AndreaNecchi @MyUniSR @SanRaffaeleMI